Oxigene: Wohin geht die Reise? - 500 Beiträge pro Seite

[Lucky72]

OXiGENE Provides Update on Near-Term Corporate Events

SOUTH SAN FRANCISCO, Calif., Feb. 10, 2011 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, today announced an update on three near-term corporate events.

* The board of directors has voted unanimously to enact a reverse stock split with a 20:1 ratio, following authorization of the reverse split by a shareholder vote on December 21, 2010. The reverse split will be effective as of February 23, 2011.
* OXiGENE anticipates receiving a ruling from NASDAQ before the end of February on the Company's requests for an exception through June 13, 2011 to regain compliance with NASDAQ's listing standards and transfer the listing of its common stock to the Nasdaq Capital Market. The Company believes that the reverse stock split will represent a positive contributing factor in NASDAQ's consideration.
* The Company also announced that the U.S. Food and Drug Administration (FDA) has granted OXiGENE's request for a meeting to discuss the results of the FACT study of ZYBRESTAT as a potential treatment for anaplastic thyroid cancer. The meeting date has been set for March 16, 2011.

"We believe that the events reported today, as well as our recently announced warrant exchange, further support our overall goal of developing effective solutions to treat cancer and eye diseases," said OXiGENE Chief Executive Officer Peter J. Langecker, M.D., Ph.D. "We look forward to providing additional updates as key events unfold."

OXiGENE expects to provide additional updates on these and other corporate activities in its fourth quarter and full year 2010 financial results press release and on its conference call, the date of which will be announced shortly.

About OXiGENE

OXiGENE is a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases. The Company's major focus is developing vascular disrupting agents that selectively disrupt abnormal blood vessels associated with solid tumor progression and visual impairment. OXiGENE is dedicated to leveraging its intellectual property and therapeutic development expertise to bring life-extending and life-enhancing medicines to patients.

The OXiGENE, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=4969

Safe Harbor Statement

This news release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Any or all of the forward-looking statements in this press release, which include the timing of the reverse split and receipt of regulatory and stock listing guidance may turn out to be wrong. Forward-looking statements can be affected by inaccurate assumptions OXiGENE might make or by known or unknown risks and uncertainties, including, but not limited to, an adverse stock listing determination and the availability of additional financing to continue development of ZYBRESTAT.

Additional information concerning factors that could cause actual results to materially differ from those in the forward-looking statements is contained in OXiGENE's reports to the Securities and Exchange Commission, including OXiGENE's reports on Form 10-K, 10-Q and 8-K. However, OXiGENE undertakes no obligation to publicly update forward-looking statements, whether because of new information, future events or otherwise. Please refer to our Annual Report on Form 10-K for the fiscal year ended December 31, 2009.

CONTACT: Investor and Media Contact:

Michelle Edwards, Investor Relations


http://investor.oxigene.com/releasedetail.cfm?ReleaseID=5490…

[Lucky72]

Hier ist der Link zur HP!

http://www.oxigene.com/

[Lucky72]

Pipeline!

[Lucky72]

Nur zur Info!

http://clinicaltrials.gov/ct2/results?term=Oxigene

[Lucky72]

[Lucky72]

[Lucky72]

[Lucky72]

Also ich hätte erwartet das sie weiter abkackt!

[Lucky72]

OXiGENE to Collaborate With NCI/CTEP, GOG on Phase 2 Study of ZYBRESTAT in Patients With Relapsed Ovarian Cancer

SOUTH SAN FRANCISCO, Calif., Feb. 14, 2011 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, announced today that it has entered into a Cooperative Research and Development Agreement with the National Cancer Institute's (NCI) Cancer Therapy Evaluation Program (CTEP) to collaborate on the conduct of a randomized Phase 2 trial of ZYBRESTAT in combination with bevacizumab in patients with relapsed ovarian cancer. Under the terms of the agreement, OXiGENE will provide ZYBRESTAT to NCI for an NCI-sponsored study conducted by the Gynecologic Oncology Group (GOG), an organization dedicated to clinical research in the field of gynecologic cancer. The aim of the trial will be to determine if the combination of ZYBRESTAT and bevacizumab will enhance anti-tumor effects and further delay tumor progression when compared to bevacizumab alone. OXiGENE anticipates that investigators will initiate enrollment in this Phase 2 study in the first quarter of 2011. The primary endpoint of the study will be progression-free survival, with results expected to become available in early 2013.

Peter J. Langecker, M.D., Ph.D., OXiGENE Chief Executive Officer, commented: "Based on the encouraging data from both an earlier Phase 2 trial of ZYBRESTAT and chemotherapy in platinum-resistant ovarian cancer, and from our FALCON study of ZYBRESTAT plus bevacizumab in non-small cell lung cancer, we have been eager to continue exploration of combination therapy in patients with relapsed ovarian cancer, which is a highly difficult-to-treat disease. The finalization of this agreement is a critical milestone for OXiGENE, and exemplifies our strategy to leverage our assets through collaborations and continue to demonstrate the therapeutic potential of our vascular disrupting agents in major tumor types. We look forward to working with the GOG and NCI/CTEP to bring this new combination to patients."

Investigators from the GOG approached OXiGENE after seeing positive data from a Phase 2 study of ZYBRESTAT and chemotherapy in patients with platinum-resistant ovarian cancer. The study announced today is designed to investigate an alternative approach to treating relapsed ovarian cancer by exclusively targeting tumor vasculature without the use of chemotherapy.

Earlier Positive Phase 2 Data in Ovarian Cancer

OXiGENE reported positive final data from an investigator-sponsored Phase 2 study of ZYBRESTAT in patients with platinum-resistant ovarian cancer at the 2009 Annual Meeting of the American Society of Clinical Oncology (ASCO). Platinum resistance was defined as disease relapse within 6 months of completing treatment with platinum-based therapy, and the patients enrolled in the study would therefore not have been expected to respond to further treatment with platinum-based therapy. Of 44 patients enrolled in the study, 11 (25%) had confirmed partial responses as determined by the Gynecologic Cancer InterGroup (GCIG) response criteria, i.e., response by tumor imaging (RECIST) and/or ovarian cancer biomarker (CA-125) criteria. An additional 4 patients had unconfirmed partial responses, and stable disease responses were reported in an additional 16 patients. The combination regimen of ZYBRESTAT and carboplatin plus paclitaxel chemotherapy was observed to be well-tolerated with approximately half of the patients completing all 6 cycles of therapy. The Phase 2 trial was a single-arm, Simon two-stage design study evaluating the safety and efficacy of the combination of ZYBRESTAT and chemotherapy (carboplatin and paclitaxel).

About the Gynecologic Oncology Group

The Gynecologic Oncology Group (GOG) is a not-for-profit organization with the purpose of promoting excellence in the quality and integrity of clinical and basic scientific research in the field of gynecologic malignancies. The GOG is committed to maintaining the highest standards in clinical trials development, execution, analysis and distribution of results. The GOG is one of the National Cancer Institute's funded cooperative groups. The GOG is the only group that focuses its research on women with pelvic malignancies, such as cancer of the ovary, uterus, and cervix. The GOG is multi-disciplinary in its approach to clinical trials, and includes gynecologic oncologists, medical oncologists, pathologists, radiation oncologists, nurses, statisticians, basic scientists, quality of life experts, data managers, and administrative personnel.

About ZYBRESTAT (fosbretabulin)

ZYBRESTAT is being evaluated in a Phase 2 study of patients with non-small cell lung cancer and other clinical trials. OXiGENE believes that ZYBRESTAT is poised to become an important product in a novel class of small-molecule drug candidates called vascular disrupting agents. Through interaction with vascular endothelial cell cytoskeletal proteins, ZYBRESTAT selectively targets and collapses tumor vasculature, thereby depriving the tumor of oxygen and causing death of tumor cells. In clinical trials in solid tumors, ZYBRESTAT has demonstrated potent and selective activity against tumor vasculature, as well as clinical activity against anaplastic thyroid cancer, ovarian cancer and various other solid tumors.

About OXiGENE

OXiGENE is a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases. The Company's major focus is developing vascular disrupting agents that selectively disrupt abnormal blood vessels associated with solid tumor progression and visual impairment. OXiGENE is dedicated to leveraging its intellectual property and therapeutic development expertise to bring life-extending and life-enhancing medicines to patients.

The OXiGENE, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=4969

Safe Harbor Statement

This news release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Any or all of the forward-looking statements in this press release, which include the timing of new clinical studies, the results of the proposed relapsed ovarian cancer study, and the efficacy of the ZYBRESTAT and bevacizumab combination may turn out to be wrong. Forward-looking statements can be affected by inaccurate assumptions OXiGENE might make or by known or unknown risks and uncertainties, including, but not limited to, the outcome of clinical studies and the availability of additional financing to continue development of ZYBRESTAT.

Additional information concerning factors that could cause actual results to materially differ from those in the forward-looking statements is contained in OXiGENE's reports to the Securities and Exchange Commission, including OXiGENE's reports on Form 10-K, 10-Q and 8-K. However, OXiGENE undertakes no obligation to publicly update forward-looking statements, whether because of new information, future events or otherwise. Please refer to our Annual Report on Form 10-K for the fiscal year ended December 31, 2009.

CONTACT: Michelle Edwards, Investor Relations

[Lucky72]

The board of directors has voted unanimously to enact a reverse stock split with a 20:1 ratio, following authorization of the reverse split by a shareholder vote on December 21, 2010. The reverse split will be effective as of February 23, 2011.

Mal sehn wo wir heute anfangen!

[Lucky72]

Keine Bewegung!

[Lucky72]

OXiGENE Announces Fourth Quarter and Fiscal 2010 Earnings Conference Call and Webcast

SOUTH SAN FRANCISCO, Calif., Feb. 28, 2011 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGND), a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, will report fourth quarter and fiscal year-end 2010 results, along with guidance for 2011, on Thursday, March 3, 2011. A conference call and webcast hosted by OXiGENE management will begin at 4:30 pm EST (1:30 p.m. PST).

To listen to a live or an archived version of the audio webcast, please log on to the Company's website, www.oxigene.com. Under the "Investors" tab, select the link to "Events & Presentations."

OXiGENE's earnings conference call can also be heard live by dialing [phone] in the United States and Canada, and [phone] for international callers, five minutes prior to the beginning of the call. A replay will be available starting at 7:30 p.m. EST, (4:30 p.m. PST) on March 3, 2011 and ending at midnight EST (9:00 p.m. PST) on Wednesday, March 9, 2011. To access the replay, please dial [phone] if calling from the United States or Canada, or [phone] from international locations. Please refer to replay pass code 44782248.

About OXiGENE, Inc.

OXiGENE is a clinical-stage biotechnology company developing novel small-molecule therapeutics to treat cancer and eye diseases. The Company's major focus is the clinical advancement of drug candidates that selectively disrupt abnormal blood vessels associated with solid tumor progression and visual impairment. OXiGENE is dedicated to leveraging its intellectual property position and therapeutic development expertise to bring life saving and enhancing medicines to patients.

The OXiGENE, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=4969

CONTACT: Michelle Edwards, Investor Relations


http://investor.oxigene.com/releasedetail.cfm?ReleaseID=5531…

[Lucky72]

[zwitscherton]

What the matter with that co.
Seems pretty f***cked up.

[Lucky72]

OXiGENE Receives Listing Decision From NASDAQ
Common Stock Trading to Transfer to the NASDAQ Capital Markets

SOUTH SAN FRANCISCO, Calif., March 2, 2011 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq: OXGND), a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, today announced that, on March 1, 2011, the Company received a determination from the NASDAQ Listing Qualifications Panel (the "Panel") enabling its Common Stock to trade on The NASDAQ Capital Market. The Company will have until June 13, 2011 to demonstrate compliance with the minimum $1.00 per share closing bid price requirement ("Bid Price") and all continued listing standards of The NASDAQ Capital Market.

As previously announced, on February 25, 2011, the Company implemented a 1-for-20 reverse stock split of its common shares in an effort to regain compliance with NASDAQ's Bid Price requirement. The Company may demonstrate compliance with the applicable requirements if its common stock has a closing bid price of at least $1.00 per share for a minimum of ten consecutive business days prior to June 13, 2011. The consolidated closing bid price for the Company's stock today was $2.27 per share. Separately, the Company must demonstrate regained compliance with the minimum market value of listed securities ("Market Capitalization") requirement and the minimum stockholders' equity ("Equity") requirement prior to June 13, 2011. While the Company expects to regain compliance with all The NASDAQ Capital Market listing requirements and satisfy all the terms of the Panel's decision, there can be no assurance that it will be able to do so.

The transfer of the Company's listing from The NASDAQ Global Market to The NASDAQ Capital Market will take effect with the open of NASDAQ trading on March 3, 2011. The Company will continue to trade under the ticker symbol OXGND through March 21, 2011. The Company's symbol will revert back to OXGN on March 22, 2011.

About OXiGENE, Inc.

OXiGENE is a clinical-stage biotechnology company developing novel small-molecule therapeutics to treat cancer and eye diseases. The Company's major focus is the clinical advancement of drug candidates that selectively disrupt abnormal blood vessels associated with solid tumor progression and visual impairment. OXiGENE is dedicated to leveraging its intellectual property position and therapeutic development expertise to bring life saving and enhancing medicines to patients.

The OXiGENE, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=4969

Safe Harbor Statement

This news release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 including the Company's anticipated ability to regain compliance in a timely manner with the Bid Price, Market Capitalization, Minimum Equity or other Nasdaq Capital Market listing requirements and satisfy all the terms of the Panel's decision. Any or all of the forward-looking statements in this press release may turn out to be wrong. Forward-looking statements can be affected by inaccurate assumptions OXiGENE might make or by known or unknown risks and uncertainties, including, but not limited to, the Company's inability to obtain additional financing or achieve the required market value of its listed securities. Additional information concerning factors that could cause actual results to materially differ from those in the forward-looking statements is contained in OXiGENE's reports to the Securities and Exchange Commission, including OXiGENE's reports on Form 10-K, 10-Q and 8-K. However, OXiGENE undertakes no obligation to publicly update forward-looking statements, whether because of new information, future events or otherwise. Please refer to our Annual Report on Form 10-K for the fiscal year ended December 31, 2009.

CONTACT: Investor and Media Contact:


http://investor.oxigene.com/releasedetail.cfm?ReleaseID=5540…

[Lucky72]

OXiGENE Reports Full Year 2010 Financial Results

SOUTH SAN FRANCISCO, Calif., March 3, 2011 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq: OXGND), a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, reported financial results for the year ending December 31, 2010. The Company also provided an update on recent clinical and corporate progress and outlook for 2011.

Financial Results

For the year ended December 31, 2010, the consolidated net loss was $23.8 million, compared with a consolidated net loss of $28.9 million for 2009. The consolidated net loss for the year ended December 31, 2010 was impacted primarily by a reduction in operating expenses of approximately $12.7 million, offset by an $8.2 million fluctuation in the gain (loss) from the change in fair value of warrants and other financial instruments — from a non-cash gain of approximately $2.2 million in the 2009 fiscal period to a noncash loss of approximately $6.0 million in the 2010 fiscal period.

The decrease in operating expenses for the twelve-month period ended December 31, 2010 over the same period in 2009 is primarily the result of OXiGENE's decision in February 2010 to implement a restructuring plan in order to focus the Company's resources on its highest-value clinical assets and reduce its cash utilization. This restructuring resulted in the discontinuation of enrollment in some of the Company's clinical programs and the reduction of its work force by approximately 49%. By this action, OXiGENE was able to reduce its average quarterly cash utilization by approximately 48 % over the course of 2010.

The net loss applicable to common stock was $5.96 per share for the year ended December 31, 2010, compared with a net loss applicable to common stock of $13.15 per share for fiscal 2009. These per share results reflect the effect of the 1:20 reverse stock split that became effective on February 22, 2011.

In fiscal 2009, OXiGENE recorded the acquisition of the Symphony ViDA variable interest entity as a capital transaction, and the $10.4 million excess of the fair market value of the shares of common stock issued to Symphony by OXiGENE ($15.6 million) over the carrying value of the non-controlling interest at the time of the acquisition ($5.2 million) is reflected as an increase in the loss applicable to common stock within the calculation of basic and diluted earnings per share for the year ended December 31, 2009.

At December 31, 2010, OXiGENE had cash, cash equivalents and restricted cash of approximately $4.7 million, compared with approximately $14.1 million at December 31, 2009.

"OXiGENE has made significant progress in advancing our clinical programs toward tangible milestones, such as the presentation of the ATC clinical data at scientific meetings in Paris and Milan and the upcoming meeting with the FDA. Furthermore, a key priority for 2010 was to simplify our balance sheet and focus on managing the company in a fiscally responsible manner," said Peter Langecker, M.D., Ph.D., OXiGENE's Chief Executive Officer. "Over the past several months we have undertaken practical, meaningful measures to strengthen our financial standing, including the reverse stock split which is now effective and which brings us towards compliance with NASDAQ listing requirements. We remain focused on maximizing the value of our ZYBRESTAT™ oncology programs through clinical progress and partnering efforts. We are looking forward to our upcoming meeting with the FDA on March 16th which should, in due course, provide us with insight into the next appropriate regulatory steps to pursue in anaplastic thyroid cancer, which is a rare but aggressive and devastating disease for which no effective therapy is available. We believe that 2011 will be a pivotal year for OXiGENE as our programs gain additional visibility within the oncology community and among potential pharmaceutical partners."

Fourth Quarter 2010 and Recent Clinical Highlights

-- In October, OXiGENE presented initial results from the FACT study, a randomized, controlled, Phase 2/3 study of ZYBRESTAT (fosbretabulin, CA4P) in patients with anaplastic thyroid cancer at the European Society for Medical Oncology (ESMO) meeting in Milan, Italy, showing an increased overall survival (OS) in patients receiving ZYBRESTAT in addition to standard chemotherapy. The data also suggested a survival benefit in multiple subgroups of patients, including patients who had more advanced Stage IVC disease, patients who were heavily pretreated with surgery, radiation or chemotherapy, and patients less than 60 years of age, who tend to have a more aggressive course of disease. Importantly, the data also showed that 23% of patients who received ZYBRESTAT and chemotherapy were alive at one year, compared with 9% of patients who received chemotherapy alone.

-- In November, OXiGENE announced positive interim data from the FALCON trial, a randomized, controlled Phase 2 study of ZYBRESTAT in patients with non-small cell lung cancer (NSCLC) at the AACR/EORTC/NCI meeting in Berlin, Germany. The combination regimen including ZYBRESTAT was observed to be well-tolerated, with no significant cumulative toxicities when compared with the control arm. The updated analysis showed that the median time to progression for patients receiving ZYBRESTAT plus bevacizumab and chemotherapy remained stable (as compared to the data presented at ASCO 2010) at 9.5 months, compared with a median time to progression of 8.8 months for patients receiving bevacizumab and chemotherapy alone. Of the patients in the study arm, 50% achieved a partial response, compared with 38% in the control arm.

Business Highlights

-- In November, OXiGENE announced that the Company was awarded $733,000 in tax credit grants by the U.S. Internal Revenue Service under a new program created as part of the Patient Protection and Affordable Care Act of 2010, called the Qualifying Therapeutic Discovery Project. The credit is a tax benefit awarded to therapeutic discovery projects that show a reasonable potential to result in new therapies that treat areas of unmet medical need or prevent, detect or treat chronic or acute diseases and conditions. OXiGENE intends to use the proceeds of the grant funds to continue its trials of ZYBRESTAT and OXi4503.

-- In January 2011, OXiGENE entered into separate Warrant Exchange Agreements with each of the holders of outstanding warrants originally issued in March 2010 to eliminate all of such warrants having "ratchet" price-based anti-dilution protection features in exchange for shares of Company common stock and a lower number of warrants having no price based anti-dilution protections.

-- The board of directors voted unanimously to implement a 1:20 reverse stock split of the Company's common stock, following authorization of the reverse split by a shareholder vote on December 21, 2010. The reverse split became effective on February 22, 2011. OXiGENE is also pursuing measures to regain compliance with NASDAQ's listing standards and is transferring the Company's listing from The NASDAQ Global Market to The NASDAQ Capital Market upon the open of NASDAQ trading on March 3, 2011.

Outlook for 2011

Acquiring additional capital to continue the development of our valued assets remains a high priority for the Company. The Company believes that the outcome of its scheduled meeting with the FDA on March 16, 2011 will be a significant factor in its ability to obtain additional financial resources, and in the amount and nature of those additional financial resources. OXiGENE will announce the outcome of that meeting as soon as practicable after receiving final minutes of the meeting from the FDA, which may not be for several weeks following the date of the meeting. Meanwhile, the Company continues to maintain a disciplined financial strategy with its remaining capital resources.

Anticipated Milestones for 2011

-- The company expects the University of Florida to initiate a Phase 1 study of OXi4503 in patients with acute myelogenous leukemia (AML) in Q1 2011, pursuant to an investigator sponsored clinical trial agreement previously entered into with OXiGENE.

-- The company expects to meet with the FDA on March 16th to discuss the results of the FACT study and to receive guidance on an appropriate regulatory path. The company plans to announce the outcome of the meeting when it receives the meeting minutes from the agency, anticipated in mid-April.

-- The company expects the Gynecologic Oncology Group (GOG) to initiate a National Cancer Institute / Cancer Therapy Evaluation Program (NCI/CTEP)-sponsored Phase 2 study of ZYBRESTAT used in conjunction with bevacizumab in patients with relapsed ovarian cancer in Q1 2011. The company announced on February 14th, 2011, that it has entered into a Cooperative Research and Development Agreement (CRADA) with NCI/CTEP to collaborate on this study. Under the terms of the agreement, OXiGENE will provide ZYBRESTAT to NCI/CTEP for an NCI/CTEP-sponsored study to be conducted by the Gynecologic Oncology Group (GOG), an organization dedicated to clinical research in the field of gynecologic cancer.

-- The company has submitted an abstract and expects to present the final data from the FACT study at ASCO in June 2011.

-- The company has submitted an abstract and expects to present additional data from the FALCON study at ASCO in June 2011.

Conference Call Today

Members of OXiGENE's management team will review fourth quarter and full-year 2010 results via a webcast and conference call today, March 3, 2011, at 4:30 p.m. ET (1:30 p.m. PST). To listen to a live or an archived version of the audio webcast, please log on to the Company's website, www.oxigene.com. Under the "Investors" tab, select the link to "Events and Presentations."

OXiGENE's earnings conference call can also be heard live by dialing [phone] in the United States and Canada, and [phone] for international callers, five minutes prior to the beginning of the call. A replay will be available starting at 7:30 p.m. EST, (4:30 p.m. PST) on March 3, 2011 and ending at midnight EST (9:00 p.m. PST) on Wednesday, March 9, 2011. To access the replay, please dial [phone] if calling from the United States or Canada, or [phone] from international locations. Please refer to replay pass code 44782248.

About OXiGENE

OXiGENE is a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases. The Company's major focus is developing vascular disrupting agents that selectively disrupt abnormal blood vessels associated with solid tumor progression and visual impairment. OXiGENE is dedicated to leveraging its intellectual property and therapeutic development expertise to bring life-extending and life-enhancing medicines to patients.

The OXiGENE, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=4969

Safe Harbor Statement

This news release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Any or all of the forward-looking statements in this press release, which include the timing of advancement, outcomes, and regulatory guidance relative to our clinical programs, achievement of our business and financing objectives and ability to regain compliance with Nasdaq listing standards may turn out to be wrong. Forward-looking statements can be affected by inaccurate assumptions OXiGENE might make or by known or unknown risks and uncertainties, including, but not limited to, the inherent risks of drug development and regulatory review, and the availability of additional financing to continue development of our programs.

Additional information concerning factors that could cause actual results to materially differ from those in the forward-looking statements is contained in OXiGENE's reports to the Securities and Exchange Commission, including OXiGENE's reports on Form 10-K, 10-Q and 8-K. However, OXiGENE undertakes no obligation to publicly update forward-looking statements, whether because of new information, future events or otherwise. Please refer to our Annual Report on Form 10-K for the fiscal year ended December 31, 2009.

http://investor.oxigene.com/releasedetail.cfm?ReleaseID=5545…

[Lucky72]

OXiGENE Receives Meeting Minutes from FDA Type C Meeting on ZYBRESTAT(TM) Anaplastic Thyroid Program

SOUTH SAN FRANCISCO, Calif., March 21, 2011 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq: OXGN), a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, announced today that it has received minutes from a Type C meeting held on March 16, 2011, between OXiGENE and the US Food and Drug Administration (FDA) to discuss next steps in the development of ZYBRESTAT as a potential treatment for anaplastic thyroid cancer (ATC).

As the company anticipated, the FDA indicated at the meeting that the data from the FACT trial are suggestive of possible clinical activity that may warrant continued development, and that to seek regulatory approval, OXiGENE should plan to conduct an additional clinical trial with a survival endpoint. The FDA also confirmed that, as the company had expected, the Special Protocol Agreement (SPA) that had been agreed upon at the start of the study is no longer in effect.

"We appreciate the candid discussions and constructive feedback we received from the FDA representatives," said Peter Langecker, Chief Executive Officer of OXiGENE. "We believe that the totality of the data, which showed that of 84 ATC patients treated with ZYBRESTAT, 20 (approximately 24%) survived one year or longer as compared to a historical rate of less than 10%, provides a compelling basis for further study."

Dr. Langecker added: "We continue to be encouraged by the outcomes in all of our clinical studies to date, including the ATC study, and are reviewing our options to further develop our VDA therapies and the additional funding that would be needed through strategic partnerships and equity financing."

The company has submitted an abstract and expects to present the final data from the FACT study, an 80-patient, randomized, controlled trial of ZYBRESTAT in combination with carboplatin and paclitaxel in patients with ATC at ASCO in June 2011.

About ZYBRESTAT (fosbretabulin)

ZYBRESTAT is being evaluated in a Phase 2 study of patients with non-small cell lung cancer and other clinical trials. OXiGENE believes that ZYBRESTAT is poised to become an important product in a novel class of small-molecule drug candidates called vascular disrupting agents. Through interaction with vascular endothelial cell cytoskeletal proteins, ZYBRESTAT selectively targets and collapses tumor vasculature, thereby depriving the tumor of oxygen and causing death of tumor cells. In clinical trials in solid tumors, ZYBRESTAT has demonstrated potent and selective activity against tumor vasculature, as well as clinical activity against anaplastic thyroid cancer, ovarian cancer and various other solid tumors.

About OXiGENE

OXiGENE is a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases. The Company's major focus is developing vascular disrupting agents that selectively disrupt abnormal blood vessels associated with solid tumor progression and visual impairment. OXiGENE is dedicated to leveraging its intellectual property and therapeutic development expertise to bring life-extending and life-enhancing medicines to patients.

The OXiGENE, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=4969

Safe Harbor Statement

This news release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Any or all of the forward-looking statements in this press release, which include additional drug development activities and availability of additional financing or business partnerships may turn out to be wrong. Forward-looking statements can be affected by inaccurate assumptions OXiGENE might make or by known or unknown risks and uncertainties, including, but not limited to, the outcome of clinical studies, the level of interest among potential business partners and the availability of additional financing to continue development of OXiGENE's VDA therapies.

Additional information concerning factors that could cause actual results to materially differ from those in the forward-looking statements is contained in OXiGENE's reports to the Securities and Exchange Commission, including OXiGENE's reports on Form 10-K, 10-Q and 8-K. However, OXiGENE undertakes no obligation to publicly update forward-looking statements, whether because of new information, future events or otherwise. Please refer to our Annual Report on Form 10-K for the fiscal year ended December 31, 2010.

CONTACT: Investor and Media Contact:


http://investor.oxigene.com/releasedetail.cfm?ReleaseID=5589…

[KillingJoke]

Antwort auf Beitrag Nr.: 41.241.632 von Lucky72 am 21.03.11 14:55:36

Hey Lucky,
ziemlich viel Copy and Paste aber keine Aussagen von Dir.
Bist Du long?
Gruss
KJ

[Lucky72]

Antwort auf Beitrag Nr.: 41.256.099 von KillingJoke am 23.03.11 20:33:56

Ich warte noch auf den richtigen Einstiegskurs!

[KillingJoke]

Antwort auf Beitrag Nr.: 41.256.271 von Lucky72 am 23.03.11 21:03:26

Das wird ziemlich schwierig.

Klar reizt Oxigene wegen der scheinbar fortgeschrittenen Pipeline.
Die Marktkapitalisierung liegt unter 15 Mio USD.
Wenn jetzt "tolle Nachrichten" kommen, dann steigt das Teil in den Himmel.

Es sind aber nur noch 5 Mio USD Cash vorhanden und jetzt will die FDA auch noch zusätzliche Tests. Das sieht für mich gar nicht gut aus.
Grossaktionär Symphony scheint auch nichts mehr reinpumpen zu wollen.

[Lucky72]

Antwort auf Beitrag Nr.: 41.256.554 von KillingJoke am 23.03.11 21:55:09

Instis sind auch nicht viele drin!

http://www.dailyfinance.com/company/oxigene-inc/oxgn/nas/ins…

Ich bin da sehr vorsichtig, und kaufe erst wenn die Instis kaufen!

[Lucky72]

OXiGENE'S Novel Cathepsin L Inhibitors Demonstrate Antitumor Efficacy in Preclinical Studies

Data Presented at AACR Underscore Therapeutic Potential of Company's Lead Preclinical Program

SOUTH SAN FRANCISCO, Calif., April 4, 2011 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq: OXGN), a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, announced the presentation of positive preclinical data supporting development of its novel, non-peptidic cathepsin L inhibitors as anticancer agents. The data were presented today at the 102nd Annual Meeting of the American Association of Cancer Research in Orlando, Florida.

Cysteine cathepsins are a family of lysosomal proteases that are often up-regulated in a variety of cancers and that have been implicated in key processes in cancer progression. Small molecule inhibitors of the cysteine protease cathepsin L have the potential to limit degradation of extracellular matrix in the normal tissue surrounding the tumor, thus retarding cancer metastasis. It has also been established that cathepsin L is involved in blood vessel development, and thus inhibitors have the potential to suppress tumor growth and dissemination through an anti-angiogenic effect.

"The discovery of new chemotherapeutic strategies for inhibiting the growth and spread of cancer, such as our novel class of cathepsin inhibitors, represents an important achievement in the effort to enhance both cancer patient quality of life and survival. We are very encouraged by the preclinical safety and efficacy data presented at the AACR meeting with our small molecule cathepsin L inhibitors. Our goal is to advance these promising agents towards clinical evaluation," said Dr. Dai Chaplin, OXiGENE's Chief Scientific Officer

In a presentation titled, Abrogation of Prostate Cancer Cell Metastatic Phenotype by Cathepsin L Inhibition, Dhivya Sudhan and Professor Dietmar Siemann from The Shands Cancer Center at The University of Florida demonstrated that OXiGENE's lead cathepsin L inhibitor, KGP94, inhibited the metastatic phenotype in the three human prostate cancer cell lines. KGP94 mediated abrogation of tumor cell migration and invasion occurred in the absence of cytotoxic effects and was a consequence of an inhibitory effect on secreted and not nuclear cathespsin-L.

Professor Siemann commented: "Our findings strongly support a mechanism of action where KGP94 affects the ability of cathepsin-L to break down extracellular matrix, which is important in invasive and angiogenic processes."

A second presentation, titled Development and Initial Evaluation of the Antitumor Activity of a Functionalized Benzophenone Thiosemicarbazone Inhibitor of Cathepsin L, by Professors Mary Lynn Trawick and Kevin G. Pinney from Baylor University and Professor Michael Horsman from Arhus University Hospital in Denmark, demonstrated that KGP94 and other structurally related compounds inhibited the invasion and migration of DU145 prostate cancer cells through matrigel. In addition, the professors presented initial in vivo data from a mouse breast cancer model showing significant antitumor effects against both recently implanted and established tumors. These antitumor effects are consistent with a mechanism impacting tumor growth and vascularization.

About OXiGENE, Inc.

OXiGENE is a clinical-stage biotechnology company developing novel small-molecule therapeutics to treat cancer and eye diseases. The Company's major focus is the clinical advancement of drug candidates that selectively disrupt abnormal blood vessels associated with solid tumor progression and visual impairment. OXiGENE is dedicated to leveraging its intellectual property position and therapeutic development expertise to bring life saving and enhancing medicines to patients.

The OXiGENE, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=4969

Forward-Looking Statements

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Any or all of the forward-looking statements in this press release, which includes statements about expectations, plans and future development of OXiGENE's technologies, may turn out to be wrong. Forward-looking statements can be affected by inaccurate assumptions OXiGENE might make or by known or unknown risks and uncertainties, including, but not limited to, the risk that the development of OXiGENE's cathepsin L inhibitor-based therapeutics may be delayed, may not proceed as planned, or may not be completed. Additional information concerning factors that could cause actual results to materially differ from those in the forward-looking statements is contained in OXiGENE's reports to the Securities and Exchange Commission, including OXiGENE's reports on Form 10-K, 10-Q and 8-K. However, OXiGENE undertakes no obligation to publicly update forward-looking statements, whether because of new information, future events or otherwise.

CONTACT: Investor and Media Contact:

http://investor.oxigene.com/releasedetail.cfm?ReleaseID=5615…

[Lucky72]

[Lucky72]

http://investor.oxigene.com/secfiling.cfm?filingID=950123-11…

[Lucky72]

Verdammt!

Hätte ich nur zu 1,60$ gekauft!!!

[Lucky72]

Zitat von Lucky72: Verdammt!

Hätte ich nur zu 1,60$ gekauft!!!

Wird vielleicht noch!

[Lucky72]

OXiGENE Reports Encouraging Data From Phase 2 Trial of ZYBRESTAT(TM) in Non-small Cell Lung Cancer

SOUTH SAN FRANCISCO, Calif., June 4, 2011 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, announced today that it presented updated safety and clinical activity data from the FALCON trial, a stratified randomized, controlled Phase 2 study of ZYBRESTAT™ (fosbretabulin tromethamine, or CA4P) in patients with non-small cell lung cancer (NSCLC), at the 2011 Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, Illinois. The data were presented in a poster by Edward Garon, M.D., Assistant Professor of Medicine at the University of California, Los Angeles and primary investigator in the study.

An updated analysis conducted approximately 11 months after the enrollment of the last patient in June 2010 showed that the combination regimen of ZYBRESTAT plus bevacizumab, carboplatin and paclitaxel (ZYBRESTAT Arm) was observed to be well-tolerated with no significant cumulative toxicities when compared with the control arm of the study. In addition, a pre-specified subgroup analysis showed meaningful improvements in median time to progression for patients with poor performance status (ECOG Performance Status 1). While the median time to progression for the overall patient population was similar in both arms of the study, 8.6 months for the ZYBRESTAT arm compared with 9.0 months on the control arm, an analysis of the patient strata showed that patients with poor performance status who received ZYBRESTAT in addition to bevacizumab and chemotherapy achieved a median time to progression of 9.8 months compared with only 3.8 months for patients in this same subgroup on the control arm of the study with a hazard ratio (95% CI) of 0.51 (0.23, 1.16).

These data were presented in a poster titled, "Randomized Phase 2 Trial of a Vascular Disrupting Agent (VDA) Fosbretabulin Tromethamine (CA4P) with Carboplatin, Paclitaxel and Bevacizumab in Stage IIIB/IV Non-Squamous Non Small Cell Lung Cancer (NSCLC): Analyses of Safety and Efficacy of the FALCON Trial," by Dr. Garon.

"The FALCON results show evidence of activity with an increased response rate in patients who were treated with the combination of ZYBRESTAT, bevacizumab and chemotherapy. Non-small cell lung cancer patients with a poorer performance status also had a clinically meaningful increase in time to progression in patients. These results are highly encouraging," said Dr. Garon. "The suggestion that this combination may be especially beneficial in a sicker patient population should be explored in a larger trial to delineate the potential of targeting more advanced patient populations with the combined effects of a vascular disrupting agent, anti-angiogenic and chemotoxic therapies."

"With several clinical trials completed in multiple indications, we now have a large body of data showing the excellent combinability potential of ZYBRESTAT," said Peter Langecker, M.D., Chief Executive Officer at OXiGENE. "In addition, this study provides data in non-small cell lung cancer suggesting that ZYBRESTAT may benefit patients with more advanced stages of disease, such as patients with ECOG 1 status. We believe that designing a development plan based on targeting this subgroup of patients could represent a sensible and achievable clinical strategy and we look forward to discussing further development of ZYBRESTAT with potential pharmaceutical partners."

FALCON is a randomized, controlled study investigating the addition of ZYBRESTAT (fosbretabulin tromethamine, or CA4P) to standard therapy (carboplatin, paclitaxel, and bevacizumab, or C/P/Bev) in patients with Stage IIIb or IV predominantly non-squamous NSCLC. Randomization was stratified by ECOG status and prior therapies. A total of 60 patients were treated with 29 in the standard therapy arm and 31 in the ZYBRESTAT + standard therapy arm (safety population). The treatment arms were well balanced except for a greater number of males in the CA4P arm. Disease was predominately Stage IV in both arms. Of the 60 patients treated, 29 were ECOG 1 status, with 16 ECOG 1 patients in the ZYBRESTAT arm and 13 ECOG 1 patients in the control arm. Patients received CA4P plus standard therapy, or standard therapy alone, every 21 days for up to 6 cycles (treatment phase). Patients without disease progression after 6 cycles could continue to receive bevacizumab with or without CA4P (depending on treatment arm) until disease progression (maintenance phase).

Key data points from the FALCON trial are as follows.

Progression-free survival (PFS)

PFS determined by RECIST criteria.
Median PFS was 8.6 months in the ZYBRESTAT arm versus 9.0 months in the standard therapy arm (HR with 95% CI: 1.05 (0.56, 1.98)).
Median PFS in patients with ECOG 0 status was 7.0 months in the ZYBRESTAT arm versus 11.5 months in the standard therapy arm (HR with 95% CI: 2.38 (1.00, 5.69)).
Median PFS in patients with ECOG 1 status was 9.8 months in the ZYBRESTAT arm versus 3.8 months in the standard therapy arm (HR with 95% CI: 0.51 (0.23, 1.16)).

Tumor response

Partial Response (PR) was 56% in the ZYBRESTAT arm and 36% in the standard therapy arm.

Tolerability

The addition of ZYBRESTAT to standard therapy appeared to be well tolerated.
Safety profiles were similar with ZYBRESTAT+ C/P/Bev and C/P/Bev.
Grade 3 hypertension was more frequent in the ZYBRESTAT arm and manageable with use of amlodipine prophylaxis or other anti-HTN medications following protocol management guidelines.
Grade 1-4 neutropenia was more frequent in the ZYBRESTAT arm, but there was no difference in dose reductions between the two treatment arms.
3 patients experienced transient and reversible cardiac ischemia that resolved within 24-72 hours.
The addition of ZYBRESTAT to C/P/Bev:

Slightly increased QTc prolongation (mostly Grade 1 or 2). 3 patients (1 in CA4P arm and 2 in C/P/Bev) had Grade 3 QTc prolongation.
Did not increase selected bevacizumab-associated safety events such as arterial thrombotic events, proteinuria, or bleeding.
Did not adversely affect renal or hepatic function.

A copy of the poster "Randomized Phase 2 Trial of a Vascular Disrupting Agent (VDA) Fosbretabulin Tromethamine (CA4P) with Carboplatin, Paclitaxel and Bevacizumab in Stage IIIB/IV Non-Squamous Non Small Cell Lung Cancer (NSCLC): Analyses of Safety and Efficacy of the FALCON Trial" is available on OXiGENE's website at www.oxigene.com.

About ZYBRESTAT (fosbretabulin tromethamine)

ZYBRESTAT is being evaluated in studies of patients with non-squamous non-small cell lung cancer, anaplastic thyroid cancer, platinum-sensitive ovarian cancer and other clinical trials. OXiGENE believes that ZYBRESTAT is poised to become an important therapeutic option in a novel class of small-molecule drug candidates called vascular disrupting agents. Through interaction with vascular endothelial cell cytoskeletal proteins, ZYBRESTAT selectively targets and collapses tumor vasculature, thereby depriving the tumor of oxygen and causing death of tumor cells. In clinical trials in solid tumors, ZYBRESTAT has shown potent and selective activity against tumor vasculature, as well as possible clinical activity against anaplastic thyroid cancer, ovarian cancer and various other solid tumors.

About OXiGENE

OXiGENE is a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases. The Company's major focus is developing vascular disrupting agents that selectively disrupt abnormal blood vessels associated with solid tumor progression and visual impairment. OXiGENE is dedicated to leveraging its intellectual property and therapeutic development expertise to bring life-extending and life-enhancing medicines to patients.

The OXiGENE, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=4969

Safe Harbor Statement

This news release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Any or all of the forward-looking statements in this press release, which include possible outcomes of clinical studies involving ZYBRESTAT, interest among potential partners or regulatory outcomes, may turn out to be wrong. Forward-looking statements can be affected by inaccurate assumptions OXiGENE might make or by known or unknown risks and uncertainties, including, but not limited to, the outcome of clinical studies and the availability of additional financing to continue development of ZYBRESTAT. Additional information concerning factors that could cause actual results to materially differ from those in the forward-looking statements is contained in OXiGENE's reports to the Securities and Exchange Commission, including OXiGENE's reports on Form 10-K, 10-Q and 8-K. However, OXiGENE undertakes no obligation to publicly update forward-looking statements, whether because of new information, future events or otherwise. Please refer to our Annual Report on Form 10-K for the fiscal year ended December 31, 2010.

CONTACT: Investor and Media Contact:

Michelle Edwards, Investor Relations

[Lucky72]

ZYBRESTAT(TM) Results Suggest Improvement in Overall Survival in Phase 2/3 Study in Anaplastic Thyroid Cancer

Median Overall Survival Extended by 1.2 Months for ZYBRESTAT Patients

One-Year Survival Almost Tripled With ZYBRESTAT Plus
Chemotherapy Compared to Chemotherapy Alone (26% vs. 9%)

ZYBRESTAT Oral Presentation Included in "Best of ASCO®"

SOUTH SAN FRANCISCO, Calif., June 6, 2011 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq: OXGN), a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, announced today that encouraging final results from a randomized, controlled, Phase 2/3 study of ZYBRESTAT (fosbretabulin tromethamine, or CA4P) in patients with anaplastic thyroid cancer (ATC) were presented today at the 2011 Annual Meeting of the American Society of Clinical Oncology (ASCO) meeting in Chicago, Illinois, by Julie Sosa, M.D., Associate Professor of Surgery and of Medicine at Yale University, and primary investigator in the study.

In this 80-patient study, the median overall survival (OS) time was 5.2 months for patients who received ZYBRESTAT and chemotherapy compared with 4.0 months for patients receiving chemotherapy alone (Hazard Ratio (95% CI) of 0.72 (0.43, 1.20)), representing a 28% reduction in the risk of death for patients receiving ZYBRESTAT and chemotherapy. For patients treated with ZYBRESTAT and chemotherapy, the likelihood of being alive at six months was 48% compared with 35% for patients treated with the control arm regimen. At one year, the likelihood of being alive was 26% for patients treated with ZYBRESTAT and chemotherapy compared with 9% for patients treated with chemotherapy alone. As in other studies of ZYBRESTAT, the most clinically relevant side effects reported in the study were neutropenia, transient hypertension, clinically asymptomatic QTc prolongation and tumor pain.

"The final FACT data suggest that patients treated with fosbretabulin plus chemotherapy experienced clinically meaningful increases in overall survival, which is a highly encouraging outcome in a patient population that has historically shown a survival rate of less than one year," said Dr. Sosa. "The suggestion of survival benefit is especially noteworthy given how quickly this cancer develops, and the observation that patients in this trial who experienced the most meaningful clinical benefit included those with poor prognostic factors and larger, more advanced tumors."

"We believe that the final data from the FACT study being presented here at ASCO confirm our earlier analyses suggesting that ZYBRESTAT may represent a potential future treatment option for ATC patients who currently have very few treatment choices for this very aggressive disease," said Peter J. Langecker, M.D., Ph.D., OXiGENE Chief Executive Officer. "We are hopeful that results presented today and featured in the "Best of ASCO" presentations will help to continue to build interest in ZYBRESTAT among potential pharmaceutical partners and the broader oncology community."

ZYBRESTAT is a vascular disrupting agent (VDA), and one of a novel class of small-molecule drug candidates. Through interaction with vascular endothelial cell cytoskeletal proteins, ZYBRESTAT selectively targets and collapses tumor vasculature, thereby depriving the tumor of oxygen and causing death of tumor cells. In clinical trials in solid tumors, ZYBRESTAT has shown potent and selective activity against tumor vasculature, as well as possible clinical activity against ATC, ovarian cancer and various other solid tumors.

ZYBRESTAT has received orphan drug designation for the treatment of anaplastic thyroid cancer, medullary thyroid cancer, and stage IV papillary or follicular thyroid cancer.

Phase 2/3 Study Key Results

The FACT Study is a randomized, controlled Phase 2/3 study investigating the addition of ZYBRESTAT to chemotherapy (carboplatin and paclitaxel) in patients with anaplastic thyroid cancer. A total of 80 patients were enrolled in the study, with 55 in the ZYBRESTAT + chemotherapy arm and 25 in the chemotherapy arm. The treatment arms were well balanced with regard to key patient characteristics except for a greater percentage of females in the control arm. Patients in the study arm received ZYBRESTAT each week and chemotherapy on day 2 of treatment every three weeks. Patients in the control arm received chemotherapy every three weeks. Patients in the study arm could elect to receive ZYBRESTAT as maintenance therapy after completing 6 cycles of therapy without progression. Maintenance therapy continued until disease progression.

Key Study Results

Median overall survival time of 5.2 months for patients receiving ZYBRESTAT and chemotherapy, compared with 4.0 months for patients receiving chemotherapy alone (HR (95% CI) of 0.72 (0.43, 1.20)).
The likelihood of 1-year survival almost tripled with ZYBRESTAT and chemotherapy vs. chemotherapy only (26% vs. 9%).
Suggestion of improved survival in patients with poor prognostic factors, such as stage IVC disease and with tumors greater than 6 cm in size, suggesting greater antitumor activity in more advanced tumors.
ZYBRESTAT in combination with chemotherapy appeared to be well tolerated, with adverse events primarily related to ATC and disease progression. Myelosuppression was more common in patients receiving ZYBRESTAT and chemotherapy, but rates of febrile neutropenia were equally low in both arms. As a result of work done in earlier studies, hypertension management guidelines were implemented and have reduced significant ZYBRESTAT-induced hypertension and cardiac ischemia.

A copy of the ASCO presentation, titled, "A randomized phase II/III trial of a tumor vascular disrupting agent fosbretabulin tromethamine (CA4P) with carboplatin (C) and paclitaxel (P) in anaplastic thyroid cancer (ATC): Final survival analysis for the FACT trial," is available on OXiGENE's website at www.oxigene.com.

The FACT oral presentation has been selected for inclusion in the Best of ASCO® program, which will be held shortly after the ASCO Annual Meeting. The Best of ASCO is an educational initiative that condenses highlights from ASCO's Annual Meeting into a two-day program and is intended to increase global access to cutting-edge science. Abstracts were selected according to specific criteria and reflect research that is relevant and significant in oncology today. In addition to two domestic Best of ASCO meetings in Miami and Seattle, there will also be approximately eighteen International Best of ASCO Meetings and various ASCO-licensed packages.

About ZYBRESTAT (fosbretabulin tromethamine)

ZYBRESTAT is being evaluated in studies of patients with ATC, non-squamous non-small cell lung cancer and platinum-sensitive ovarian cancer. OXiGENE believes that ZYBRESTAT is poised to become an important therapeutic option in a novel class of small-molecule drug candidates called vascular disrupting agents. Through interaction with vascular endothelial cell cytoskeletal proteins, ZYBRESTAT selectively targets and collapses tumor vasculature, thereby depriving the tumor of oxygen and causing death of tumor cells. In clinical trials in solid tumors, ZYBRESTAT has demonstrated potent and selective activity against tumor vasculature, as well as possible clinical activity against anaplastic thyroid cancer, ovarian cancer and other solid tumors.

About OXiGENE

OXiGENE is a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases. The Company's major focus is developing vascular disrupting agents that selectively disrupt abnormal blood vessels associated with solid tumor progression and visual impairment. OXiGENE is dedicated to leveraging its intellectual property and therapeutic development expertise to bring life-extending and life-enhancing medicines to patients.

The OXiGENE, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=4969

Safe Harbor Statement

This news release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Any or all of the forward-looking statements in this press release, which include possible outcomes of clinical studies involving ZYBRESTAT, regulatory outcomes or interest among potential partners may turn out to be wrong. Forward-looking statements can be affected by inaccurate assumptions OXiGENE might make or by known or unknown risks and uncertainties, including, but not limited to, the outcome of clinical studies and the availability of additional financing to continue development of ZYBRESTAT. Additional information concerning factors that could cause actual results to materially differ from those in the forward-looking statements is contained in OXiGENE's reports to the Securities and Exchange Commission, including OXiGENE's reports on Form 10-K, 10-Q and 8-K. However, OXiGENE undertakes no obligation to publicly update forward-looking statements, whether because of new information, future events or otherwise. Please refer to our Annual Report on Form 10-K for the fiscal year ended December 31, 2010.

CONTACT: Investor and Media Contact:

Michelle Edwards, Investor Relations

[Lucky72]

Vielleicht kommt ja doch bald 1€!

[Lucky72]

OXiGENE Announces Restructuring to Focus Resources on Promising Earlier Stage Clinical Programs

SOUTH SAN FRANCISCO, Calif., Sept. 1, 2011 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, announced today a restructuring plan designed to focus the Company's capital resources on its most promising early-stage clinical programs and further reduce its cash utilization. Key aspects of the restructuring and its effects on the Company's current and planned clinical trials are as follows:

At this time, a Company sponsored Phase 3 registrational study of ZYBRESTAT in patients with anaplastic thyroid cancer (ATC) funded by Company financial resources is not feasible. OXiGENE will continue to explore options for conducting such a study, including potential collaborations with national and international head and neck cancer cooperative groups. Future development decisions concerning ZYBRESTAT in patients with ATC will be made following a review of all options by OXiGENE's management and its board of directors.

OXiGENE is concluding its Phase 2 ZYBRESTAT trial in non-small cell lung cancer (FALCON study). At this time, no decision regarding further development of the study of ZYBRESTAT in patients with NSCLC has been made. Any future development decisions concerning the study of ZYBRESTAT in patients with NSCLC will be made following review of final data by OXiGENE's management and its board of directors.

OXiGENE plans to continue its investigator-sponsored Phase 1 trial of OXi4503 in patients with AML or myelodysplastic syndrome (MDS), being conducted at the University of Florida and with support by The Leukemia & Lymphoma Society's Therapy Acceleration Program.

OXiGENE plans to continue its randomized Phase 2 trial of ZYBRESTAT in combination with bevacizumab in patients with relapsed ovarian cancer, which is an NCI-sponsored study conducted by the Gynecologic Oncology Group (GOG), an organization dedicated to clinical research in the field of gynecologic cancer.

OXiGENE will evaluate additional early-stage development opportunities for its two product candidates, ZYBRESTAT and OXi4503, subject to available resources at the time.

The Company is reducing its workforce by 11 full-time equivalent employees or approximately 61%.

The Company will seek to reduce the amount of space it currently rents to conduct its operations as soon as practicable.

"OXiGENE's management and board have determined that the optimal course of action is to focus on advancing our earlier stage clinical development programs while completing the trials we or clinical investigators have initiated," said Peter Langecker, M.D., Ph.D., OXiGENE's Chief Executive Officer. "We were hopeful that we could further the development of ZYBRESTAT in anaplastic thyroid cancer with internal financial resources, but, in light of the challenges in funding such a rare orphan disease, that is not possible at the present time. The dire need of ATC patients for an effective therapy remains, however, and we intend to explore the feasibility of conducting the FACT 2 trial under National Cancer Institute's Cancer Therapy Evaluation Program sponsorship. Focusing our clinical resources on what we believe are our most promising early-stage clinical development opportunities and reducing our operating costs should allow us to conserve available resources. A reduction in force is never an easy decision to make, especially as we have such an excellent team here at OXiGENE. We want to express our sincere appreciation and gratitude to the employees who are affected by this restructuring, and we wish them well in future endeavors."

The Company is offering severance benefits to the terminated employees, and anticipates recording a total charge of approximately $1,200,000, primarily associated with personnel-related termination costs. In order to provide for an orderly transition, the Company intends to implement the reduction in work force in a phased manner. Therefore approximately $1,100,000 of the restructuring charge will be taken in the third quarter of 2011, with the remainder being taken over the following two quarters as the transition is effected. Substantially all of the charge is expected to represent cash expenditures. The Company anticipates that, with its current financial resources together with the amount remaining on its At-the-Market financing facility of $634,000, it will be able to complete the ongoing clinical studies outlined above. Should the Company decide to initiate additional studies, it would need to raise additional capital. Upon completion of the restructuring activities outlined above, the Company expects to reduce expenses from its current levels by an annual amount of approximately $2,000,000.

About OXiGENE, Inc.

OXiGENE is a clinical-stage biotechnology company developing novel small-molecule therapeutics to treat cancer and eye diseases. The Company's major focus is the clinical advancement of drug candidates that selectively disrupt abnormal blood vessels associated with solid tumor progression and visual impairment. OXiGENE is dedicated to leveraging its intellectual property position and therapeutic development expertise to bring life saving and enhancing medicines to patients.

The OXiGENE, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=4969

About ZYBRESTAT (fosbretabulin tromethamine / CA4P)

ZYBRESTAT is being evaluated in studies of patients with anaplastic thyroid cancer, non-squamous non-small cell lung cancer, platinum-sensitive ovarian cancer and other clinical trials. OXiGENE believes that ZYBRESTAT has the potential to become an important therapeutic option in a novel class of small-molecule drug candidates called vascular disrupting agents. Through interaction with vascular endothelial cell cytoskeletal proteins, ZYBRESTAT selectively targets and collapses tumor vasculature, thereby depriving the tumor of oxygen and causing death of tumor cells. In clinical trials in solid tumors, ZYBRESTAT has suggested potent and selective activity against tumor vasculature, as well as possible clinical activity against anaplastic thyroid cancer, ovarian cancer and various other solid tumors.

About OXi4503

OXi4503 (combretastatin A1 di-phosphate / CA1P) is a dual-mechanism vascular disrupting agent (VDA) that is being developed in clinical trials for the treatment of leukemias and solid tumors. Like its structural analog ZYBRESTAT, OXi4503 has been observed to block and destroy tumor vasculature, resulting in extensive tumor cell death and necrosis. In addition, preclinical data indicate that OXi4503 is metabolized by oxidative enzymes (e.g., tyrosinase and peroxidases), which are elevated in many solid tumors and tumor white blood cell infiltrates, to an orthoquinone chemical species that has direct cytotoxic effects on tumor cells. Preclinical studies have shown that OXi4503 has single-agent activity against a range of xenograft tumor models; and synergistic or additive effects when incorporated in various combination regimens with chemotherapy, molecularly-targeted therapies (including tumor-angiogenesis inhibitors), and radiation therapy. OXi4503 has been evaluated as a monotherapy in a Phase 1 dose-escalation trial in patients with advanced solid tumors and in patients with cancers involving the liver.

Safe Harbor Statement

This news release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Any or all of the forward-looking statements in this press release, which include the timing of advancement or outcomes of our clinical programs and achievement of our business and financing objectives may turn out to be wrong. Forward-looking statements can be affected by inaccurate assumptions OXiGENE might make or by known or unknown risks and uncertainties, including, but not limited to, the inherent risks of drug development and regulatory review, and the availability of additional financing to continue development of our programs.

Additional information concerning factors that could cause actual results to materially differ from those in the forward-looking statements is contained in OXiGENE's reports to the Securities and Exchange Commission, including OXiGENE's reports on Form 10-K, 10-Q and 8-K. However, OXiGENE undertakes no obligation to publicly update forward-looking statements, whether because of new information, future events or otherwise. Please refer to our Annual Report on Form 10-K for the fiscal year ended December 31, 2010.

CONTACT: OXiGENE, Inc.

http://investor.oxigene.com/releasedetail.cfm?ReleaseID=6026…

[Kursziel1000]

Partnership oder Buyout news sollen bald veröffentlicht werden.
Aktueller Kurs $1.33

[Kursziel1000]

$OXGN termination of Kingsbridge $40M deal means OXGN gonna face a buyout or a partnership with a huge biotech company!
I am buying all I can below $1.30 !

http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=81894…

Termination of a Material Definitive Agreement.

On October 13, 2011, OXiGENE, Inc. (the “Company”) notified Kingsbridge Capital Limited (“Kingsbridge”) of the termination of its Committed Equity Financing Facility (“CEFF”) with Kingsbridge, pursuant to which Kingsbridge had committed to purchase, subject to certain conditions, up to $40 million of the Company’s common stock. Effective as of October 14, 2011, the CEFF was terminated by the Company pursuant to Section 8.2(c) of the common stock purchase agreement (the “Common Stock Purchase Agreement”) with Kingsbridge, dated as of February 19, 2008, as amended.

In connection with the CEFF, on February 19, 2008, OXiGENE also issued a warrant (the “Warrant”) to Kingsbridge to purchase up to 12,500 shares of OXiGENE common stock. The Warrant remains exercisable until August 19, 2013, subject to certain conditions.

[Kursziel1000]

New letter from CEO
http://www.oxigene.com/files/Letter_from_CEO_oct132011.pdf

...On the clinical front, shortly we expect to have the final overall survival data from our completed Phase 2 study in non-small cell lung cancer (the FALCON study) which compared the standard chemotherapy treatment regimen for these patients, consisting of
carboplatin, paclitaxel and bevacizumab with and without ZYBRESTAT. We hope to be ready to talk about these results at our upcoming quarterly earnings call in November 2011....

[Lucky72]

OXiGENE Presents Data Confirming Survival Benefit of ZYBRESTAT in Patients With Anaplastic Thyroid Cancer

SOUTH SAN FRANCISCO, Calif., Sept. 14, 2011 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq: OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, today presented data from a retrospective comparative analysis suggesting that treatment with ZYBRESTAT (fosbretabulin, or CA4P) confers a one-year survival benefit in patients with anaplastic thyroid cancer (ATC) compared to treatment with chemotherapy alone. The data derive from a comparison between the results of the company's aggregate data from five independent prospective Phase 1 and Phase 2 trials using ZYBRESTAT to treat patients with ATC, including the FACT trial, and data from the 50-year experience in treating ATC patients at the Mayo Clinic, Rochester, MN (Mayo Group) from 1949-1999, published by Dr. Bryan McIver, one of the world's leading experts in treating patients with ATC. OXiGENE's FACT trial is the largest single, randomized, controlled, multi-center clinical trial ever conducted in ATC, and the Mayo studies comprise the largest retrospective review of the treatment outcomes in ATC conducted at a single institution. The FACT data were originally presented at the 2011 ASCO meeting by Dr. Julie Sosa from Yale Medical School, New Haven, CT.

The data were presented at the 35th Meeting of the European Thyroid Association, in Krakow, Poland, in a presentation titled, "Comparison of 1-year Survival between Patients with Anaplastic Thyroid Cancer (ATC) treated with Fosbretabulin (CA4P) in 5 Independent Prospective Studies and a Large Single Institution Historical Series." The presenter was Rossella Elisei, M.D., Department of Endocrinology, University of Pisa, Italy.

Key findings and conclusions from the retrospective analysis presented today were:

13 patients or 9.7% of all 134 ATC patients treated at the Mayo Clinic survived one year or more.

19 patients or 23% of all 84 ATC patients treated with ZYBRESTAT either alone or in combination with chemotherapy survived more than one year. The longest survival is 13+ years in a patient with a complete response.

The 9% rate of patients in the control arm of the FACT study surviving one year is almost identical to the observed 9% in the much larger Mayo cohort, underscoring the meaningfulness of the 24% rate in the FACT study in terms of a suggested survival benefit.

As is often the case with historical data, direct comparisons between the FACT trial and the Mayo Group have to be interpreted with the caveat that there were changes in standard-of-care treatment over the past 50 years, as well as differences in staging, sample size, and time-to-death analysis (i.e., survival time was computed from the time of randomization in FACT while Mayo group used time of diagnosis as the starting point). This slight imbalance in the calculation of time to death, however, would favor the Mayo group in terms of a slightly longer calculated survival.

The increased one-year survival rate with ZYBRESTAT was seen in patients with larger tumors.

Peter J. Langecker, M.D., Ph.D., OXiGENE's CEO, commented on the importance of the comparative analysis: "We undertook this retrospective analysis to further elucidate the clinical relevance of the survival benefit with ZYBRESTAT shown in the FACT trial, with particular focus on comparing the control group's outcomes on chemotherapy alone with the Mayo Clinic's group. Despite some of the different characteristics in the two sets of studies, the one-year survival benefit for patients in the control group and the patients in the cohort treated at the Mayo Clinic is nearly identical, with fewer than 10% of patients alive after one year.

"The 24% of patients treated with ZYBRESTAT in the FACT study surviving one year or longer remains striking in its significance. Patients treated with ZYBRESTAT essentially had a one-in-four chance of being alive after one year compared to only a one-in-10 chance in the control group, which corresponds to the survival outcome in the Mayo Clinic treated group.

"Sadly, one must conclude that over the past 50 years, as reflected in the Mayo study, treatment outcomes have remained poor for patients with ATC in spite of general advances in diagnosis, surgical techniques, available chemotherapeutic agents and supportive care, underscoring the critical need for new, improved therapeutic options beyond standard chemotherapy. This is the reason why the FACT survival data, even without a p-value due to the 80-patient sample size, have been so favorably received by the ATC community. We are working closely with many of the clinicians and experts who see ATC patients in the U.S. and abroad, and we remain hopeful that we will be able to advance ZYBRESTAT to a registration trial and potentially make a meaningful contribution to the treatment paradigm for this highly lethal tumor."

A copy of the data presented today is available on the OXiGENE website: www.oxigene.com.

About ZYBRESTAT

ZYBRESTAT is being evaluated in a Phase 2 study of patients with non-squamous non-small cell lung cancer and other clinical trials, including a recently completed Phase 2 study of ZYBRESTAT plus chemotherapy in patients with anaplastic thyroid cancer (ATC). OXiGENE believes that ZYBRESTAT is poised to become an important product in a novel class of small-molecule drug candidates called vascular disrupting agents. Through interaction with vascular endothelial cell cytoskeletal proteins, ZYBRESTAT selectively targets and collapses tumor vasculature, thereby depriving the tumor of oxygen and causing death of tumor cells. In clinical trials in solid tumors, ZYBRESTAT has demonstrated potent and selective activity against tumor vasculature, as well as clinical activity against anaplastic thyroid cancer, ovarian cancer and various other solid tumors.

About OXiGENE, Inc.

OXiGENE is a clinical-stage biotechnology company developing novel small-molecule therapeutics to treat cancer and eye diseases. The Company's major focus is the clinical advancement of drug candidates that selectively disrupt abnormal blood vessels associated with solid tumor progression and visual impairment. OXiGENE is dedicated to leveraging its intellectual property position and therapeutic development expertise to bring life-saving and enhancing medicines to patients.

The OXiGENE, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=4969

Safe Harbor Statement

This press release contains forward-looking statements that reflect management's current views regarding OXiGENE's continued product development operations and the value and potential of OXiGENE's product candidates in development may turn out to be wrong. Forward-looking statements can be affected by inaccurate assumptions OXiGENE might make or by known or unknown risks and uncertainties, including, but not limited to, the outcome of clinical studies and the availability of additional financing to continue development of ZYBRESTAT. Additional information concerning factors that could cause actual results to materially differ from those in the forward-looking statements is contained in OXiGENE's reports to the Securities and Exchange Commission, including OXiGENE's reports on Form 10-K, 10-Q and 8-K. However, OXiGENE undertakes no obligation to publicly update forward-looking statements, whether because of new information, future events or otherwise. Please refer to our Annual Report on Form 10-K for the fiscal year ended December 31, 2010.

CONTACT: Investor and Media Contact:

http://investor.oxigene.com/releasedetail.cfm?ReleaseID=6055…

[Lucky72]

OXiGENE Reports Final Data From Phase 2 FALCON Study of ZYBRESTAT in Non-Small Cell Lung Cancer

SOUTH SAN FRANCISCO, Calif., Nov. 3, 2011 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq: OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, announced final results today from the FALCON trial, a stratified, randomized, controlled Phase 2 study of ZYBRESTAT™ (fosbretabulin tromethamine, or CA4P) in patients with advanced non-small cell lung cancer (NSCLC).

The final analysis of the data showed that the combination regimen of ZYBRESTAT plus bevacizumab, carboplatin and paclitaxel (ZYBRESTAT arm) was observed to be well-tolerated with no significant cumulative toxicities or overlapping toxicities with bevacizumab when compared with the control arm of the study (standard chemotherapy plus bevacizumab). In addition, an analysis of patients with tumor burden greater than 10 cm suggested meaningful improvements in overall survival for patients receiving ZYBRESTAT in addition to bevacizumab and chemotherapy. For patients with this large tumor burden, median overall survival was 14.2 months, compared with 11.0 months for patients on the control arm of the study. For the overall patient population, no survival benefit was observed for patients receiving ZYBRESTAT.

"This final data reinforces our earlier observations that ZYBRESTAT in combination with bevacizumab and chemotherapy may have therapeutic utility for patients with large or hard-to-treat tumors and who appear not to be as well served by the standard therapy of carboplatin, paclitaxel and bevacizumab. The data also suggest that that two vascular targeting agents, ZYBRESTAT and bevacizumab, can be administered in combination with a manageable side effect profile. These results are suggestive and present an opportunity for further clinical exploration in the future," said Peter Langecker, M.D., Chief Executive Officer at OXiGENE. "OXiGENE's major focus remains on working towards a global registrational study of ZYBRESTAT in anaplastic thyroid cancer, including obtaining the necessary financing for such a study, as well as supporting our ongoing clinical program in ovarian cancer and earlier stage programs. We are extremely grateful to the patients and physicians who participated in the FALCON study."

FALCON is a randomized, controlled study investigating the addition of ZYBRESTAT to standard therapy (carboplatin, paclitaxel, and bevacizumab, or C/P/Bev) in patients with Stage IIIb or IV predominantly non-squamous NSCLC. Randomization was stratified by ECOG status and prior therapies. A total of 60 patients were treated, with 29 in the standard therapy or control arm and 31 in the ZYBRESTAT + standard therapy arm. The treatment arms were well balanced except for a greater percentage of male patients in the CA4P arm. Disease was predominantly Stage IV in both arms. Patients received CA4P plus standard therapy, or standard therapy alone, every 21 days for up to 6 cycles (treatment phase). Patients without disease progression after 6 cycles could continue to receive bevacizumab with or without CA4P (depending on treatment arm) until disease progression (maintenance phase).

Key data points from the FALCON trial are as follows.

Overall Survival (OS)

OS determined by patients' survival status at last follow up.

Median OS was 13.6 months in the ZYBRESTAT arm versus 16.2 months in the standard therapy arm (HR with 95% CI: 1.06 (0.55, 2.03)).

Median OS in patients with aggregate tumor burden greater than 10 cm was 14.2 months in the ZYBRESTAT arm versus 11.0 months in the standard therapy arm (HR with 95% CI: 0.67 (0.26, 1.70)).

Median OS in patients with aggregate tumor burden of 10 cm or less was 13.6 months in the ZYBRESTAT arm versus 16.7 months in the standard therapy arm (HR with 95% CI: 1.38 (0.51, 3.74)).

Tolerability

The addition of ZYBRESTAT to standard therapy appeared to be well tolerated.

No significant overlapping toxicities with bevacizumab were observed.

Hypertension was increased in patients in the ZYBRESTAT arm of the study but was transient and manageable without significant cardiac toxicity.

Myelosuppression was increased in patients in the ZYBRESTAT arm of the study but did not result in significant dose reductions, sepsis or discontinuation of treatment.

Progression Free Survival (PFS):

PFS determined by RECIST criteria.

Median PFS was 8.6 months in the ZYBRESTAT arm versus 9.3 months in the standard therapy arm (HR with 95% CI: 1.04 (0.57, 1.91)).

Median PFS in patients with ECOG 0 status was 7.0 months in the ZYBRESTAT arm versus 11.6 months in the standard therapy arm (HR with 95% CI: 2.12 (0.93, 4.83)).

Median PFS in patients with ECOG 1 status was 9.8 months in the ZYBRESTAT arm versus 3.8 months in the standard therapy arm (HR with 95% CI: 0.51 (0.23, 1.16)).

As previously reported, best tumor response in terms of partial response (PR) was 56% in the ZYBRESTAT arm and 36% in the standard therapy arm.

About ZYBRESTAT

OXiGENE believes that ZYBRESTAT is poised to become an important therapeutic option in a novel class of small-molecule drug candidates called vascular disrupting agents. Through interaction with vascular endothelial cell cytoskeletal proteins, ZYBRESTAT selectively targets and collapses tumor vasculature, thereby depriving the tumor of oxygen and causing death of tumor cells. In clinical trials in solid tumors, ZYBRESTAT has shown potent and selective activity against tumor vasculature, as well as possible clinical activity against anaplastic thyroid cancer, ovarian cancer and various other solid tumors.

About OXiGENE

OXiGENE is a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases. The Company's major focus is developing vascular disrupting agents that selectively disrupt abnormal blood vessels associated with solid tumor progression and visual impairment. OXiGENE is dedicated to leveraging its intellectual property and therapeutic development expertise to bring life-extending and life-enhancing medicines to patients.
http://investor.oxigene.com/releasedetail.cfm?ReleaseID=6208…

[Lucky72]

OXiGENE Reports Third Quarter 2011 Financial Results

SOUTH SAN FRANCISCO, Calif., Nov. 9, 2011 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq: OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, reported financial results for the quarter and nine months ending September 30, 2011 and provided an update on recent clinical and corporate progress.

Financial Results

For the three months ended September 30, 2011, the Company reported a net loss of $3.5 million or $0.25 per share, compared with a net loss of $13.5 million or $3.47 per share for the comparable three-month period in 2010. The change in net loss from the 2010 three-month period to the net loss in the 2011 three-month period was driven primarily by a non-recurring non-cash loss resulting from the change in fair value of warrants and other financial instruments in the 2010 three month period of $9.9 million and a reduction in research and development expenses of $1.3 million, offset by a one-time restructuring charge of $1.1 million.

The Company reported a net loss for the nine-month period ended September 30, 2011 of $7.3 million or $0.74 per share, compared with a net loss of $22.0 million or $6.24 per share for the same nine-month period of 2010. The difference in results for the comparable nine-month periods was due primarily to the non-cash change in fair value of warrants and other financial instruments from a $7.0 million loss in the 2010 nine-month period to a $2.2 million gain in the 2011 nine- month period and by a reduction in research and development expenses of $5.6 million.

The reduction in ongoing operating costs and expenses for both the three and nine month comparable periods is primarily attributable to reductions in spending in a number of clinical program and support costs in connection with the restructuring plan implemented in the first quarter of 2010.

On September 1, 2011, the Company announced a restructuring plan designed to focus the Company's capital resources on its most promising early-stage clinical programs and further reduce its cash utilization. In connection with this restructuring, which included a reduction in its workforce by 11 full-time equivalent employees or approximately 61%, the Company recognized approximately $1.1 million in restructuring expenses in the quarter ended September 30, 2011. The restructuring expenses include severance payments, health and medical benefits and related taxes, which are expected to be paid through the end of fiscal 2012. The Company anticipates that, with its current financial resources, it will be able to support the completion of its current ongoing clinical studies. Upon completion of the restructuring activities, the Company expects to reduce expenses from its current levels by an annual amount of approximately $2,000,000. In the first quarter of 2010, the Company recognized approximately $0.5 million in restructuring expenses.

During the nine months ended September 30, 2011, the Company sold approximately 7.7 million shares of common stock pursuant to an "at the market" (ATM) sales agreement executed in July 2010, resulting in net proceeds to the Company of approximately $17.0 million.

At September 30, 2011, OXiGENE had cash, cash equivalents and restricted cash of approximately $12.7 million compared with approximately $4.7 million at December 31, 2010.

"I am pleased to report that we have continued to make meaningful progress in key strategic areas in the third quarter of 2011: streamlining operations to conserve cash; working towards obtaining financing so that we can advance our most promising ZYBRESTAT clinical program in anaplastic thyroid cancer (ATC) toward a pivotal registration study; establishing collaborations for high-value clinical programs, such as ZYBRESTAT in ovarian cancer and OXi4503 in acute myelogenous leukemia, that offset our expenses and enable them to advance without direct cost to the company; and maintaining a reasonable level of investment in our earlier stage programs," said Peter J. Langecker, M.D., Ph.D., OXiGENE's Chief Executive Officer.

Continued Dr. Langecker: "Key ATC-related activities have been to line up investigators from all over the world to participate in a FACT 2 trial as well as to develop the pivotal trial protocol. We have made excellent progress in these areas, so that once we have secured funding, reviewed a potential registration pathway with the FDA and finalized preparations, we may have the potential to accelerate enrollment and potentially shorten the timeline to trial completion. We are hopeful of initiating the FACT 2 trial in 2012."

Conference Call Today

Members of OXiGENE's management team will review third quarter 2011 results via a webcast and conference call today, November 9, 2011, at 4:30 p.m. EST (1:30 p.m. PST). To listen to a live or an archived version of the audio webcast, please log on to the Company's website, www.oxigene.com. Under the "Investors" tab, select the link to "Events and Presentations."

OXiGENE's earnings conference call can also be heard live by dialing [phone] in the United States and Canada, and [phone] for international callers, five minutes prior to the beginning of the call. A replay will be available starting at 7:30 p.m. EST, (4:30 p.m. PST) on November 9, 2011 and ending at midnight EST (9:00 p.m. PST) on Tuesday, November 15, 2011. To access the replay, please dial 855-859-2056 if calling from the United States or Canada, or 404-537-3406 from international locations. Please refer to replay pass code 23578279.

About OXiGENE

OXiGENE is a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases. The Company's major focus is developing vascular disrupting agents that selectively disrupt abnormal blood vessels associated with solid tumor progression and visual impairment. OXiGENE is dedicated to leveraging its intellectual property and therapeutic development expertise to bring life-extending and life-enhancing medicines to patients.
http://investor.oxigene.com/releasedetail.cfm?ReleaseID=6224…

[Lucky72]

Nix los bei der Aktie! Ich hoffe hier kommt bald was!

[Lucky72]

Nix los!?

[Lucky72]

Nicht gut!

OXiGENE Receives Notice Related to NASDAQ Minimum Closing Bid Price Rule

SOUTH SAN FRANCISCO, Calif., June 27, 2012 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, announced it has received a notice from the Listing Qualifications Department of the NASDAQ Stock Market indicating that, for the last 30 consecutive business days, the bid price for the Company's common stock had closed below the minimum $1.00 per share required for continued inclusion on The NASDAQ Capital Market under NASDAQ Listing Rule 5550(a)(2). The notification letter states that pursuant to NASDAQ Listing Rule 5810(c)(3)(A) the Company will be afforded 180 calendar days, or until December 24, 2012 to regain compliance with the minimum closing bid price requirement. In order to regain compliance, shares of the Company's common stock must maintain a minimum closing bid price of at least $1.00 per share for a minimum of ten consecutive business days. If the Company does not regain compliance by December 24, 2012, NASDAQ will provide written notification to the Company that the Company's common stock will be delisted. At that time, the Company may appeal NASDAQ's delisting determination to a NASDAQ Listing Qualifications Panel. If the Company satisfies all of the requirements for listing on The NASDAQ Capital Market set forth in NASDAQ Listing Rule 5505, other than the minimum bid price requirement, the Company may be eligible for an additional 180 day grace period. The notification letter has no effect at this time on the listing of the Company's common stock on The NASDAQ Capital Market.

OXiGENE intends to actively monitor the bid price for its common stock during the 180-day compliance period. During this period, OXiGENE intends to continue to pursue and execute on strategies that are designed to enhance the value of its assets, in particular, its plans to advance its lead product candidate ZYBRESTAT® to a pivotal Phase 3 program in anaplastic thyroid cancer (ATC). The Company believes that focusing on advancing its ATC program toward registration, while leveraging the market incentives for orphan indications, represents the most promising near-term opportunity for value creation.

The Company is also maintaining a secondary focus on ongoing programs, such as its Phase 2 program in advanced ovarian cancer in collaboration with the Gynecologic Oncology Group, and its OXi4503 program in acute myelogenous leukemia (AML), which could also represent meaningful longer-term opportunities. Most recently, OXiGENE in-licensed rights to a promising program in neuroendocrine tumors, an orphan cancer indication that represents a large and growing market opportunity, with the goal of advancing ZYBRESTAT to a Phase 2 program in the near term. The Company is also taking steps to shore up its cash position and fund its clinical programs through key inflection points. OXiGENE's concentration on small, niche, orphan indications is consistent with its strategy of focusing on programs that may represent meaningful clinical breakthroughs for patients, significant commercial opportunities for the Company and value creating events for its investors.

http://investor.oxigene.com/releasedetail.cfm?ReleaseID=6869…

[zwitscherton]

Antwort auf Beitrag Nr.: 43.344.962 von Lucky72 am 02.07.12 20:54:03

Nicht gut !
Das erklärt wohl mit den Kursverlauf der letzten Tage.
Aber noch ist Zeit bis 24.Dez.

##

[Lucky72]

Antwort auf Beitrag Nr.: 43.351.739 von zwitscherton am 04.07.12 13:47:52

Kaufen oder noch warten, das ist hier die Frage!?

Sieht jedenfalls langsam nach Bodenbildung aus!

IMO

[Lucky72]

Kurs geht wieder runter!

Ich dachte schon ich hab was verpasst!

[Lucky72]

OXiGENE Announces Presentation at BIO-Europe Conference on November 14th

SOUTH SAN FRANCISCO, Calif., Nov. 5, 2012 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq: OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, announced that Peter Langecker, M.D., PhD., President and Chief Executive Officer, will provide a corporate overview at the 18th annual BIO-Europe international partnering conference on November 14, 2012 at 12:30 GMT at the CCH Congress Center, Hamburg, Germany. BIO-Europe is Europe's largest partnering conference, serving the global biotechnology industry. The conference annually attracts leading dealmakers from the biotechnology, pharmaceutical and finance industries, with 1,596 companies from 48 countries participating in 2011.

About OXiGENE

OXiGENE is a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer. The Company's major focus is developing vascular disrupting agents (VDAs) that selectively disrupt abnormal blood vessels associated with solid tumor progression. OXiGENE is dedicated to leveraging its intellectual property and therapeutic development expertise to bring life-extending and life-enhancing medicines to patients.

The OXiGENE, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=4969

Safe Harbor Statement

This news release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Any or all of the forward-looking statements in this press release, which include the timing of advancement, outcomes, and regulatory guidance relative to our clinical programs, achievement of our business and financing objectives may turn out to be wrong. Forward-looking statements can be affected by inaccurate assumptions OXiGENE might make or by known or unknown risks and uncertainties, including, but not limited to, the inherent risks of drug development and regulatory review, and the availability of additional financing to continue development of our programs.

Additional information concerning factors that could cause actual results to materially differ from those in the forward-looking statements is contained in OXiGENE's reports to the Securities and Exchange Commission, including OXiGENE's reports on Form 10-K, 10-Q and 8-K. However, OXiGENE undertakes no obligation to publicly update forward-looking statements, whether because of new information, future events or otherwise. Please refer to our Annual Report on Form 10-K for the fiscal year ended December 31, 2011.

CONTACT: Investor and Media Contact:

http://investor.oxigene.com/releasedetail.cfm?ReleaseID=7187…

[Lucky72]

TICK - TACK - TICK - TACK.....

Die Zeit läuft!

OXiGENE Receives Notice Related to NASDAQ Minimum Closing Bid Price Rule

SOUTH SAN FRANCISCO, Calif., June 27, 2012 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq: OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, announced it has received a notice from the Listing Qualifications Department of the NASDAQ Stock Market indicating that, for the last 30 consecutive business days, the bid price for the Company's common stock had closed below the minimum $1.00 per share required for continued inclusion on The NASDAQ Capital Market under NASDAQ Listing Rule 5550(a)(2). The notification letter states that pursuant to NASDAQ Listing Rule 5810(c)(3)(A) the Company will be afforded 180 calendar days, or until December 24, 2012 to regain compliance with the minimum closing bid price requirement. In order to regain compliance, shares of the Company's common stock must maintain a minimum closing bid price of at least $1.00 per share for a minimum of ten consecutive business days. If the Company does not regain compliance by December 24, 2012, NASDAQ will provide written notification to the Company that the Company's common stock will be delisted. At that time, the Company may appeal NASDAQ's delisting determination to a NASDAQ Listing Qualifications Panel. If the Company satisfies all of the requirements for listing on The NASDAQ Capital Market set forth in NASDAQ Listing Rule 5505, other than the minimum bid price requirement, the Company may be eligible for an additional 180 day grace period. The notification letter has no effect at this time on the listing of the Company's common stock on The NASDAQ Capital Market.

OXiGENE intends to actively monitor the bid price for its common stock during the 180-day compliance period. During this period, OXiGENE intends to continue to pursue and execute on strategies that are designed to enhance the value of its assets, in particular, its plans to advance its lead product candidate ZYBRESTAT® to a pivotal Phase 3 program in anaplastic thyroid cancer (ATC). The Company believes that focusing on advancing its ATC program toward registration, while leveraging the market incentives for orphan indications, represents the most promising near-term opportunity for value creation.

The Company is also maintaining a secondary focus on ongoing programs, such as its Phase 2 program in advanced ovarian cancer in collaboration with the Gynecologic Oncology Group, and its OXi4503 program in acute myelogenous leukemia (AML), which could also represent meaningful longer-term opportunities. Most recently, OXiGENE in-licensed rights to a promising program in neuroendocrine tumors, an orphan cancer indication that represents a large and growing market opportunity, with the goal of advancing ZYBRESTAT to a Phase 2 program in the near term. The Company is also taking steps to shore up its cash position and fund its clinical programs through key inflection points. OXiGENE's concentration on small, niche, orphan indications is consistent with its strategy of focusing on programs that may represent meaningful clinical breakthroughs for patients, significant commercial opportunities for the Company and value creating events for its investors.

[Lucky72]

RS 12:1

[lunatics]

OXiGENE Announces Granting of Orphan Drug Status in Europe for ZYBRESTAT in Ovarian Cancer

+40%

[Lucky72]

Reuters) - Oxigene Inc said on Tuesday that its experimental drug Zybrestat combined with Roche's big selling cancer drug Avastin significantly slowed progression of recurrent ovarian cancer better than Avastin alone in a midstage clinical trial.

Shares of tiny Oxigene, which had been halted prior to announcement of the trial results, more than doubled in extended trading.

The drugs, which use different mechanisms to deprive tumors of blood supply and oxygen needed to grow, met the primary goal of the study by demonstrating a statistically significant increase in progression-free survival (PFS), or the time it takes before the cancer begins to worsen.

Details of the magnitude of PFS in the 107-patient Phase II study were expected to be disclosed at a future medical meeting, and patients will be followed to see if the drug combination leads to an overall survival benefit, the company said.

"This promising combination warrants further evaluation particularly given the significant need for new treatment options in relapsed ovarian cancer," Dr. Bradley Monk, lead investigator of the study, said in a statement.

The Gynecologic Oncology Group conducted the trial under sponsorship of the Cancer Therapy Evaluation Program of the National Cancer Institute (NCI).

Avastin, a multibillion-dollar drug, is used against several kinds of cancer, including colon, lung, kidney and brain cancers. It is not approved to treat ovarian cancer in the United States, but is in other countries.

"Zybrestat is the first vascular disrupting agent to show a statistically significant progression-free survival benefit, and we are evaluating next steps to advance this combination to patients in need," Oxigene Chief Executive Peter Langecker said in a statement.

Patients taking Zybrestat had a higher incidence of high blood pressure than those who received Avastin alone, the company said. All of those patients were treated with antihypertensive medicine.

Oxigene shares jumped to $5.30 in after hours trading from a Nasdaq close at $2.42.

(Reporting by Bill Berkrot; Editing by David Gregorio)

http://www.reuters.com/article/2014/03/11/us-oxigene-cancer-…